Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iRITUX: Personalized Rituximab in Membranous Nephropathy
NCT06341205Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Feb 2025
- Primary completion
- Aug 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in membranous nephropathy (MN), sponsored by Centre Hospitalier Universitaire de Nice. Started Feb 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT06341205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341205.